- Home
- PRLD vs CELU Comparison
PRLD vs CELU Comparison
Compare PRLD & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- CELU
- Stock Information
- Founded
- PRLD 2016
- CELU 2016
- Country
- PRLD United States
- CELU United States
- Employees
- PRLD N/A
- CELU N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- CELU Health Care
- Exchange
- PRLD Nasdaq
- CELU Nasdaq
- Market Cap
- PRLD 44.0M
- CELU 42.2M
- IPO Year
- PRLD 2020
- CELU N/A
- Fundamental
- Price
- PRLD $1.01
- CELU $3.73
- Analyst Decision
- PRLD Strong Buy
- CELU Buy
- Analyst Count
- PRLD 3
- CELU 1
- Target Price
- PRLD $4.00
- CELU $6.00
- AVG Volume (30 Days)
- PRLD 133.9K
- CELU 91.6K
- Earning Date
- PRLD 08-14-2025
- CELU 10-15-2025
- Dividend Yield
- PRLD N/A
- CELU N/A
- EPS Growth
- PRLD N/A
- CELU N/A
- EPS
- PRLD N/A
- CELU N/A
- Revenue
- PRLD $7,000,000.00
- CELU $54,220,000.00
- Revenue This Year
- PRLD N/A
- CELU $23.29
- Revenue Next Year
- PRLD N/A
- CELU N/A
- P/E Ratio
- PRLD N/A
- CELU N/A
- Revenue Growth
- PRLD N/A
- CELU 138.11
- 52 Week Low
- PRLD $0.61
- CELU $1.00
- 52 Week High
- PRLD $5.95
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- PRLD 52.78
- CELU 60.16
- Support Level
- PRLD $0.75
- CELU $3.03
- Resistance Level
- PRLD $0.96
- CELU $4.31
- Average True Range (ATR)
- PRLD 0.08
- CELU 0.30
- MACD
- PRLD 0.01
- CELU 0.01
- Stochastic Oscillator
- PRLD 67.87
- CELU 56.22
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.